Multi-Organ Tissue Models Head to the International Space Station to Accelerate Discovery for Neurological, Cardiac, Metabolic, and Systemic Diseases ERIE, CO – July 1, 2026 — Sachi Bio, a biotechnology company pioneering RNA-based therapeutics through its proprietary Nanoligomer™ platform, announced the successful completion of an orbital mission that advanced ADDISTM (Accelerated Drug Discovery in Space)—the company’s multi-organ, multi-indication discovery platform. The
